Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemlineâ€™s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial.  Behind its lead, Stemline is developing a broad portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. In addition, Stemline has built a robust discovery platform called â€œStemScreenÂ®â€ which the Company has utilized to identify multiple compounds that target and impair cancer stem cells.  Stemline also possesses a comprehensive intellectual property portfolio that includes the earliest filings in the cancer stem cell field covering cancer stem cell-directed therapeutics, diagnostics, and drug screening.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemlineâ€™s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial.  Behind its lead, Stemline is developing a broad portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. In addition, Stemline has built a robust discovery platform called â€œStemScreenÂ®â€? which the Company has utilized to identify multiple compounds that target and impair cancer stem cells.  Stemline also possesses a comprehensive intellectual property portfolio that includes the earliest filings in the cancer stem cell field covering cancer stem cell-directed therapeutics, diagnostics, and drug screening.

Context Therapeutics LLC

Context Therapeutics (NASDAQ:CNTX) has announced that its clinical trial collaborator, Stemline Therapeutics Inc, a wholly-owned subsidiary of The Menarini Group, has received approval from the US Food and Drug Administration (FDA) for ORSERDU (elacestrant) for the treatment of postmenopausal women or adult men with estrogen receptor–positive (ER+), HER2-negative (HER2-), Estrogen Receptor 1 gene (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. The Philadelphia-based women's oncology company noted that ORSERDU has shown improved efficacy over the current standard-of-care (SOC) treatment, fulvestrant, in patients with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.

Context Therapeutics says clinical partner Stemline Therapeutics receives FDA approval for ORSERDU to treat certain breast cancers

Stemline Therapeutics (STML) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Stemline Therapeutics (STML) Might Surprise This Earnings Season

MacroGenics

Protagonist Therapeutics

Here's what's behind their impressive market performances.

3 Small-Cap Biotech Stocks That Surged Last Week

The ultimate binary event caused the biotech's shares to jump.

Here's Why Stemline Therapeutics Doubled Overnight

The New York-based oncology-focused, commercial-stage biopharma Stemline Therapeutics Inc (NASDAQ: STML) ringed in merger Monday with a go-private deal valued at up to $667 million.

Stemline Therapeutics To Go Private In $667M Transaction

Privately held Menarini Group, an Italian drug and diagnostics company, said Monday it has agreed to acquire Stemline Therapeutics Inc.

Italy's Menarini Group to acquire Stemline Therapeutics in deal valued at up to $677 million

FLORENCE, Italy and NEW YORK, May  04, 2020  (GLOBE NEWSWIRE) -- Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreement under which Menarini Group will acquire Stemline in a transaction valued up to $677 million.

Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

Stemline Therapeutics (STML) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Stemline Therapeutics (STML) Report Negative Q1 Earnings? What You Should Know

KalVista Pharma

Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost more than 59% over the past 52 weeks through April 10.

Wall Street Recommends Buying These 2 Falliing Knives

Wall Street Recommends Buying These 2 Falling Knives: KALV & STML

Stemline Therapeutics, Inc. (STML) CEO Ivan Bergstein on Q4 2019 Results - Earnings Call Transcript

Stemline Therapeutics (STML) delivered earnings and revenue surprises of 2.56% and 0.08%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Stemline Therapeutics (STML) Reports Q4 Loss, Tops Revenue Estimates

Stemline Therapeutics: Down, But Not Out

The launch of blood cancer drug Elzonris is slowing.

Here's Why Stemline Therapeutics Dropped Today

Karyopharm Therapeutics

2 Small Biotech Stocks To Buy For 2020

Shares have lost a third of their value since my August recommendation.

Stemline Therapeutics: Post-ASH Update For This Leader In The CD123 Space

NEW YORK, Dec.  06, 2019  (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced the appointment of Robert M. Francomano as Chief Commercial Officer.

Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer

Stemline Therapeutics, Inc. (STML) CEO Ivan Bergstein on Q3 2019 Results - Earnings Call Transcript

NEW YORK, Oct.  08, 2019  (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS® (tagraxofusp) clinical data from the pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN) was selected for oral presentation at the 81st Annual Meeting of the Japanese Society of Hematology (JSH), to be held from October 11 – 13, 2019, at the Tokyo International Forum in Tokyo, Japan.

Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology

NEW YORK, Oct.  01, 2019  (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, presented updated clinical data on the felezonexor (SL-801) Phase 1 trial in patients with advanced solid tumors at the European Society of Medical Oncology (ESMO) 2019 Annual Congress in Barcelona, Spain. The presentation is now available on the Stemline website,  www.stemline.com , under the Scientific Presentations tab.

Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress

NEW YORK, Sept.  27, 2019  (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that clinical data on felezonexor (SL-801) has been selected for presentation at the upcoming European Society of Medical Oncology (ESMO) Annual Congress 2019 to be held from September 25-30, in Barcelona, Spain. The details of the presentation are outlined below.

Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress

NEW YORK, Sept.  26, 2019  (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd at 9:30 AM ET at the Intercontinental Barclay Hotel in New York City. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.

Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

The stock of Stemline Therapeutics has fallen approximately 30% from recent highs over the past month.

Stemline Therapeutics: Still A Believer

NEW YORK, Sept.  18, 2019  (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 9:30 AM ET at the Sofitel Hotel in New York City. A live webcast of the presentation can be viewed on the company's website at  www.stemline.com .

Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference

NEW YORK, Sept.  05, 2019  (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 12:30 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation can be viewed on the company's website at  www.stemline.com .

News for Stemline Therapeutics Stock (STML)